Royce & Associates LP Boosts Holdings in Innoviva, Inc. $INVA

Royce & Associates LP boosted its holdings in shares of Innoviva, Inc. (NASDAQ:INVA) by 641.2% in the third quarter, HoldingsChannel.com reports. The fund owned 505,906 shares of the biotechnology company’s stock after buying an additional 437,654 shares during the quarter. Royce & Associates LP’s holdings in Innoviva were worth $9,233,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of INVA. Elevation Point Wealth Partners LLC purchased a new position in shares of Innoviva during the 2nd quarter worth approximately $43,000. EverSource Wealth Advisors LLC lifted its stake in Innoviva by 297.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,795 shares in the last quarter. Asset Management One Co. Ltd. acquired a new stake in Innoviva during the 3rd quarter valued at $60,000. Toth Financial Advisory Corp purchased a new position in Innoviva during the third quarter worth $63,000. Finally, Lazard Asset Management LLC purchased a new position in Innoviva during the second quarter worth $92,000. Hedge funds and other institutional investors own 99.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on INVA shares. Zacks Research downgraded Innoviva from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Innoviva in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and set a $35.00 price target on shares of Innoviva in a report on Thursday, February 26th. Cantor Fitzgerald boosted their price objective on shares of Innoviva from $29.00 to $31.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Finally, HC Wainwright upped their price objective on shares of Innoviva from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Innoviva has an average rating of “Moderate Buy” and an average price target of $38.17.

Innoviva Trading Down 2.3%

NASDAQ INVA opened at $22.30 on Wednesday. The company has a market cap of $1.67 billion, a P/E ratio of 7.31 and a beta of 0.42. Innoviva, Inc. has a 12 month low of $16.52 and a 12 month high of $25.15. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.64 and a quick ratio of 13.85. The company has a 50-day moving average of $20.98 and a 200-day moving average of $20.10.

Innoviva (NASDAQ:INVA) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $1.60. Innoviva had a net margin of 65.92% and a return on equity of 37.63%. The business had revenue of $114.61 million for the quarter, compared to analysts’ expectations of $102.62 million. As a group, equities analysts predict that Innoviva, Inc. will post 0.33 earnings per share for the current year.

Innoviva News Summary

Here are the key news stories impacting Innoviva this week:

• Positive Sentiment: HC Wainwright kept a strong stance on INVA with a “Buy” rating and a lofty $46.00 price target, and published multi-year EPS projections that imply substantial upside in 2026–2027 (their FY2026 and 2027 quarterly forecasts are materially higher than the Street consensus). This bullish posture supports upside sentiment and is a key reason investors may be bidding the stock higher today.
• Positive Sentiment: Cantor Fitzgerald raised its price target on INVA to $32 from $31, signaling incremental analyst optimism and adding to positive momentum. Cantor Fitzgerald Lifts PT
• Neutral Sentiment: Sector/peer disruption: news that Theravance Biopharma’s Phase 3 trial failed and the company is restructuring is moving respiratory/biotech headlines; impact on Innoviva is indirect unless investors re‑price royalty/partner exposures—this is a watch item but not a direct company announcement. Theravance Biopharma Plummets Theravance Restructures
• Negative Sentiment: HC Wainwright trimmed several near‑term EPS forecasts for INVA (Q1–Q4 2026 quarter-by-quarter cuts and a FY2026 reduction from $2.23 to $1.96). Specific downgrades included Q1 2026 (from $0.45 to $0.42), Q2 2026 (from $0.56 to $0.51), Q3 2026 (from $0.57 to $0.48) and Q4 2026 (from $0.66 to $0.55). Those downward revisions are a negative signal for near-term earnings momentum and could cap upside despite the high price targets.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.